A Study of ARRY-371797 in Patients With Active Ankylosing Spondylitis
Stopped early · Phase 2 · Has a placebo group
Conditions studied: Ankylosing Spondylitis
In brief
This is a Phase 2 study, involving a 12-week treatment period, designed to evaluate the effectiveness of investigational study drug ARRY-371797 (versus placebo) in treating ankylosing spondylitis, and to further evaluate the drug's safety. Approximately 130 patients from the US, Canada, Poland and Hungary will be enrolled in this study.
Key facts
- Study ID
- NCT00811499
- Run by
- Pfizer
- People needed
- 25
- Starts
- 2008-12-16
- Expected to finish
- 2009-09-29
- Last updated by the study team
- 2020-10-19
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Cedars-Sinai Medical Center — Los Angeles, California, United States
- Northwestern University — Chicago, Illinois, United States
- Westroads Medical Group — Omaha, Nebraska, United States
- Lynn Health Science Institute — Oklahoma City, Oklahoma, United States
- Oregon Health & Science University — Portland, Oregon, United States
- Low Country Rheumatology — Charleston, South Carolina, United States
- Arthritis Northwest — Spokane, Washington, United States
- Rheumatology Research Associates Group — Edmonton, Alberta, Canada
- University of Manitoba — Winnipeg, Manitoba, Canada
- Credit Valley Rheumatology — Mississauga, Ontario, Canada
- Center de Recherche Musculo-Squelettique — Trois-Rivières, Quebec, Canada
- University of Saskatchewan — Saskatoon, Saskatchewan, Canada
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.